Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski; James Moon; J. Philip Kuebler; Craig R. Nichols; David R Gandara; Howard Ozer; Stephen K. Williamson; James N. Atkins; David E. Schuller; John F. Ensley

doi:10.1080/07357900701209061

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski, James Moon, J. Philip Kuebler, Craig R. Nichols, David R Gandara, Howard Ozer, Stephen K. Williamson, James N. Atkins, David E. Schuller, John F. Ensley

Hematology and Oncology

Research output: Contribution to journal › Article

27 Scopus citations

Abstract

Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

Original language	English (US)
Pages (from-to)	182-188
Number of pages	7
Journal	Cancer Investigation
Volume	25
Issue number	3
DOIs	https://doi.org/10.1080/07357900701209061
State	Published - Apr 2007

Fingerprint

Keywords

Carboplatin
Chemotherapy
Docetaxel
Head and neck cancer
Taxane

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

Samlowski, W. E., Moon, J., Kuebler, J. P., Nichols, C. R., Gandara, D. R., Ozer, H., Williamson, S. K., Atkins, J. N., Schuller, D. E., & Ensley, J. F. (2007). Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study. Cancer Investigation, 25(3), 182-188. https://doi.org/10.1080/07357900701209061

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. / Samlowski, Wolfram E.; Moon, James; Kuebler, J. Philip; Nichols, Craig R.; Gandara, David R; Ozer, Howard; Williamson, Stephen K.; Atkins, James N.; Schuller, David E.; Ensley, John F.

In: Cancer Investigation, Vol. 25, No. 3, 04.2007, p. 182-188.

Research output: Contribution to journal › Article

Samlowski, WE, Moon, J, Kuebler, JP, Nichols, CR, Gandara, DR, Ozer, H, Williamson, SK, Atkins, JN, Schuller, DE & Ensley, JF 2007, 'Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study', Cancer Investigation, vol. 25, no. 3, pp. 182-188. https://doi.org/10.1080/07357900701209061

Samlowski, Wolfram E. ; Moon, James ; Kuebler, J. Philip ; Nichols, Craig R. ; Gandara, David R ; Ozer, Howard ; Williamson, Stephen K. ; Atkins, James N. ; Schuller, David E. ; Ensley, John F. / Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. In: Cancer Investigation. 2007 ; Vol. 25, No. 3. pp. 182-188.

@article{00d8ebd40bec41d3a5a2c82776896752,

title = "Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study",

abstract = "Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.",

keywords = "Carboplatin, Chemotherapy, Docetaxel, Head and neck cancer, Taxane",

author = "Samlowski, {Wolfram E.} and James Moon and Kuebler, {J. Philip} and Nichols, {Craig R.} and Gandara, {David R} and Howard Ozer and Williamson, {Stephen K.} and Atkins, {James N.} and Schuller, {David E.} and Ensley, {John F.}",

year = "2007",

month = apr

doi = "10.1080/07357900701209061",

language = "English (US)",

volume = "25",

pages = "182--188",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)

T2 - A Southwest Oncology Group phase II study

AU - Samlowski, Wolfram E.

AU - Moon, James

AU - Kuebler, J. Philip

AU - Nichols, Craig R.

AU - Gandara, David R

AU - Ozer, Howard

AU - Williamson, Stephen K.

AU - Atkins, James N.

AU - Schuller, David E.

AU - Ensley, John F.

PY - 2007/4

Y1 - 2007/4

N2 - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

AB - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

KW - Carboplatin

KW - Chemotherapy

KW - Docetaxel

KW - Head and neck cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=34347270591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347270591&partnerID=8YFLogxK

U2 - 10.1080/07357900701209061

DO - 10.1080/07357900701209061

M3 - Article

C2 - 17530488

AN - SCOPUS:34347270591

VL - 25

SP - 182

EP - 188

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -

Access to Document

10.1080/07357900701209061